當(dāng)前位置：
Biomedica 公司NT-proBNP ELISA Kit 簡(jiǎn)介
更新時(shí)間：2014-03-23
點(diǎn)擊次數(shù)：1204
NT-proBNP ELISA Kit （Cat.No.SK-1204）
為什么要檢測(cè)NT-proBNP ？
NT-proBNP是 proBNP分解后的76氨基酸片段。proBNP是心臟為彌補(bǔ)收縮無力而增大時(shí)，心壁被拉伸時(shí)由心臟釋放到血液中的化學(xué)物質(zhì)。一旦從心臟釋放到血液中，proBNP就會(huì)分割為NT-proBNP和BNP。由于NT-proBNP的半衰期為120min，相比之下，BNP的半衰期僅20min。所以NT-proBNP可追蹤的時(shí)間可達(dá)24h而BNPzui多可監(jiān)測(cè)的時(shí)間為1h。因此，檢測(cè)血清/血漿中的NT-proBNP穩(wěn)定性更好，檢測(cè)結(jié)果更可靠，是有效的心衰檢測(cè)工具。
應(yīng)用領(lǐng)域：
- 心臟衰竭、急性心肌梗死（左心室功能不全）
- 腎衰竭
- 肥胖癥和糖尿病
- 各種形式的繼發(fā)性高血壓
- 心衰患者的療效監(jiān)測(cè)
產(chǎn)品優(yōu)勢(shì)：
- 性價(jià)比高
- 可用于每個(gè)實(shí)驗(yàn)室或開放實(shí)驗(yàn)室
- CE 標(biāo)志-可用于臨床診斷
- 簡(jiǎn)單-傳統(tǒng)96孔板
- 動(dòng)態(tài)檢測(cè)范圍廣-可用于早期心衰檢測(cè)
試劑盒特點(diǎn)：
檢測(cè)方法：夾心ELISA，HRP/TMB顯色，12x8 板條
樣本類型：血清
樣品量：50ul/test
標(biāo)準(zhǔn)品范圍：0-640 pmol/L
檢測(cè)靈敏度：3pmol/L
孵育條件：3h/30min
單位換算：1pmol/L=8.475pg/ml
參考文獻(xiàn)：
1 | Infliximab Treatment Increases Left Ventricular Ejection Fraction in Patients with Rheumatoid Arthritis: Assessment of Heart Function by Echocardiography, Endothelin 1, Interleukin 6, and NT-pro Brain Natriuretic Peptide. PRZEMYSLAW J,et al. J Rheumatol, Apr 2012; 39: 701 - 706. |
2 | Left Ventricular Function Impairment in Patients With Normal-Weight Obesity: Contribution of Abdominal Fat Deposition, Profibrotic State, Reduced Insulin Sensitivity, and Proinflammatory Activation. Wojciech Kosmala,et al. Circ Cardiovasc Imaging, May 2012; 5: 349 - 356. |
3 | Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence..Malini Govindan,et al. Europace, Sep 2012; 14: 1302 - 1310. |
4 | Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Begoña López,et al. Cardiovasc Res, Jul 2013; 99: 111 - 120. |
5 | High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia. Raoul Stahrenberg,et al. J. Neurol. Neurosurg. Psychiatry, May 2013; 84: 479 - 487. |
6 | Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease. Shailen Sutaria,et al. Heart, Apr 2012; 98: 615 - 622. |
7 | Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery. Shih-Hsien Sung,et al. Heart, Apr 2011; 97: 648 - 654. |
8 | Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Afif F EL-Khuffash,et al. Arch. Dis. Child. Fetal Neonatal Ed., Mar 2011; 96: F133 - F137. |
9 | Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Vanessa M. McDonald,et al. Age Ageing, Jan 2011; 40: 42 – 49 |
10 | Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure. C Wu,et al. Zhonghua Xin Xue Guan Bing Za Zhi, Jul 2010; 38(7): 579-83. |
11 | Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interact CardioVasc Thorac Surg, Sep 2009; 9: 421 - 425 |
12 | Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interactive CardioVascular and Thoracic Surgery, Sep 2009; 9: 421 - 425. |
13 | Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. John K. Kjekshus,et al. Eur J Heart Fail, Aug 2009; 11: 771 – 778 |
14 | Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Tatiana Kuznetsova,et al. Circ Heart Fail, Mar 2009; 2: 105 - 112. |
